EUCTR2005-004149-33-GB进行中（未招募）不适用
A randomized, controlled trial of the effect of Osigraft when used in the treatment of displaced femoral neck fractures – a pilot study
Stryker Biotech, LLC0 个研究点开始时间: 2005年11月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for study participation, a subject must meet all of the following criteria:
- •1. Subject is willing and able to understand, sign and date the study specific, Institutional Review Board/Ethics Committee approved patient informed consent and applicable privacy regulations.
- •2. Subject must require surgical treatment of a displaced intra-capsular femoral neck fracture.
- •3. Subject must undergo definitive surgical intervention within 48 hours of the fracture.
- •4. Subject is skeletally mature (=18 years of age or radiographic evidence of closure of epiphyses).
- •5. Subject will be less than 80 years of age at the time of study treatment.
- •6. Subject was able to ambulate independently prior to femoral neck fracture.
- •7. Subject agrees to participate in the post-operative clinical evaluations.
- •8. Subject is male, or female of non-childbearing potential, or female with a negative pregnancy test within 48 hours of definitive surgical intervention.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •To be eligible for study participation, a patient must not meet any of the following criteria:
- •1. Subject is a pregnant or nursing woman, or a woman planning to become pregnant within 1 year following treatment.
- •2. Subject is of childbearing potential and is unwilling to use medically acceptable contraceptive methods such as surgical sterilization, hormonal contraceptives, barrier methods, or intrauterine devices so as to prevent pregnancy for one year following the internal fixation.
- •3. Subject has received another experimental drug, biologic or device as part of a study concurrent to or within 3 months prior to giving informed consent for this study.
- •4. Subject has a known hypersensitivity to any of the components of the product (e.g. recombinant human osteogenic protein (rhOP-1), type I bovine bone collagen matrix or other protein pharmaceuticals (e.g. monoclonal antibodies, gamma globulins)).
- •5. Subject who has a clinically significant organic disease, including cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or established dementia or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial or potentially decrease survival or interfere with ambulation or rehabilitation.
- •6. Subject has a history of malignancy.
- •7. Subject whose fracture is the result of a tumor or infection.
- •8. Subject with known metabolic bone disease or other condition (other than osteoporosis) which would negatively impact on the bone healing process (e.g. history of Paget’s disease or other osteodystrophy).
- •9. Subject has a history of pathological fractures.
- •10. Subject has a history of heterotropic ossification.
- •11. Subject is receiving treatment with a drug that interferes with bone metabolism.
- •12. Subject currently being treated with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed).
- •13. Subject has radiographic evidence of osteoarthritis in the injured hip.
- •14. Subject has a history of rheumatoid arthritis.
- •15. Subject has other fractures that would interfere with ambulation or rehabilitation.
- •16. Subject has previously received a bone morphogenic protein (e.g. Osigraft).
- •17. Subject has had previous surgical intervention at the fracture site.
- •18. Subject has a condition which places him/her at risk for osteomyelitis.
- •19. Subject has an ASA Physical Status Classification greater than 2.
- •20. Subject has a life expectancy less than 24 months.
- •21. Subject whose fracture is anticipated to be reduced in an open procedure.
研究者
相似试验
招募中
不适用
A Study on the Efficacy of Opioid-Free Anesthesia in Pediatric Cardiac SurgeryAtrial septal defect and ventricular septal defectJPRN-UMIN000043809Okayama University Hospital40
进行中（未招募）
1 期
A randomized study of the efficacy and safety of OncoGel™ treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with localized or loco-regional esophageal cancerlocalized or loco-regional esophageal cancerMedDRA version: 9.1Level: LLTClassification code 10015362Term: Esophageal cancerEUCTR2007-005051-42-BEProtherics Salt Lake City, Inc124
进行中（未招募）
不适用
A randomized study of the efficacy and safety of OncoGel™ treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with localized or loco-regional esophageal cancerlocalized or loco-regional esophageal cancerMedDRA version: 9.1Level: LLTClassification code 10015362Term: Esophageal cancerEUCTR2007-005051-42-CZProtherics Salt Lake City, Inc156
尚未招募
2 期
A randomised controlled trial evaluating the use of Motivational Interviewing compared to usual care to increase physical activity in people living in the community after a hip fracturehip fracture rehabilitation - increasing activityhip fracture rehabilitation - quality of lifehip fracture rehabilitation - mental healthMusculoskeletal - Other muscular and skeletal disordersACTRN12613000680763Dr Paul O'Halloran from La Trobe University24
已完成
4 期
ow dose zoledronate in postmenopausal women with thin bonesMusculoskeletal - OsteoporosisOsteoporosisACTRN12607000576426niversity of Auckland180